No matches

30 search results for: disease modification

EADV 2025
Congress
17
September
2025
Congress
EADV 2025 Congress

ADVENT at EADV 2025: Join Sanofi and Regeneron for three educational symposia on AD, CSU, and BP.

View more
European Society for Pediatric Dermatology (ESPD) 2024 | Košice, Slovakia
Congress
3
May
2024
Congress
European Society for Pediatric Dermatology (ESPD) 2024 | Košice, Slovakia

Inflammatory processes drive AD both within and beyond the skin, leading to significant, cumulative life impacts. Early intervention has the potential to mitigate these impacts by altering the disease course.

View more
World Congress of Dermatology (WCD) 2023 | Singapore
Congress
4
July
2023
Congress
World Congress of Dermatology (WCD) 2023 | Singapore

Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.

View more
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
Congress
8
April
2025
Congress
ADVENT at WCPD 2025

The ADVENT symposium at the 15th World Congress of Pediatric Dermatology (WCPD) will focus on discussions around disease modification in atopic dermatitis (AD) in three main topic areas: restoring the skin barrier, reducing non-atopic comorbidities, and stopping the atopic march in pediatric patients with AD aged 6 months to 11 years.

View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: South AfricaChange country/region